These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24528632)

  • 1. Tusanqi and hepatic sinusoidal obstruction syndrome.
    Wang JY; Gao H
    J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
    Gao H; Li N; Wang JY; Zhang SC; Lin G
    J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
    Lin G; Wang JY; Li N; Li M; Gao H; Ji Y; Zhang F; Wang H; Zhou Y; Ye Y; Xu HX; Zheng J
    J Hepatol; 2011 Apr; 54(4):666-73. PubMed ID: 21146894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
    Yang XQ; Ye J; Li X; Li Q; Song YH
    World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
    J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
    Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
    Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
    Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
    BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report.
    Zheng Q; Zhang H
    Medicine (Baltimore); 2024 Mar; 103(11):e37341. PubMed ID: 38489699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
    Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
    Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
    Zhang F; Zhou Y; Yang X; Xiong AZ; Wang ZT; Yang L
    Acta Pharmacol Sin; 2019 Jun; 40(6):781-789. PubMed ID: 30367152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
    Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
    Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.
    Guo T; Li X; Yang X; Kong X; Liu H; Bai T; Xu K; Ye J; Song Y
    Sci Rep; 2019 Feb; 9(1):1231. PubMed ID: 30718698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gynura Segetum Related Hepatic Sinusoidal Obstruction Syndrome: A Liver Disease with High Mortality and Misdiagnosis Rate.
    Ou P; Liu X; Tang Z; Hou Z; Liu L; Liu J; Zhou S; Fang Z; Sun K; Chen Y; Chen X; Li Y; Chen J
    Curr Pharm Des; 2019; 25(35):3762-3768. PubMed ID: 31589115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features.
    Zhou H; Wang YX; Lou HY; Xu XJ; Zhang MM
    Korean J Radiol; 2014; 15(2):218-25. PubMed ID: 24643319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
    Li YS; Bao J; Xu Y; Wang TL
    Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations.
    Chen Z; Huo JR
    Neth J Med; 2010 Jun; 68(6):252-60. PubMed ID: 20558855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review.
    Tan Y; Zheng S
    Open Med (Wars); 2023; 18(1):20230737. PubMed ID: 37333448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Xiong A; Lu L; Jiang K; Wang X; Chen Y; Wang X; Zhang W; Zhuge Y; Huang W; Li L; Liao Q; Yang F; Liu P; Ding L; Wang Z; Yang L
    Arch Toxicol; 2024 Aug; 98(8):2557-2576. PubMed ID: 38703205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bear bile powder attenuates senecionine-induced hepatic sinusoidal obstruction syndrome in mice.
    Jiang KY; Zhang Y; Ye XL; Xiong F; Chen Y; Jia XL; Zhang YX; Yang L; Xiong AZ; Wang ZT
    Chin J Nat Med; 2022 Apr; 20(4):270-281. PubMed ID: 35487597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Wang W; Chen Y; Yin Y; Wang X; Ye X; Jiang K; Zhang Y; Zhang J; Zhang W; Zhuge Y; Chen L; Peng C; Xiong A; Yang L; Wang Z
    Arch Toxicol; 2022 Jul; 96(7):2003-2019. PubMed ID: 35357534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.